What caused the sharp rise in operating profit for AstraZeneca in Q3 2023?

The sharp rise in operating profit for AstraZeneca in Q3 2023 can be attributed to **Revenue Growth** and **Cost Management**.

1. **Revenue Growth**: AstraZeneca's total revenue for Q3 2023 was $11.49 billion. Although this was slightly below the expected revenue, it is important to note that the company has shown a history of robust revenue growth in previous quarters. For instance, in Q2 2023, the company's revenue rose by 6% year-over-year to $11.42 billion, surpassing estimates by $400 million. This indicates that AstraZeneca's revenue growth trend is positive, which contributes to the increase in operating profit.

|code|Ticker|Name|Date|Revenue Surprise|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2022 Q4||1.1207E10|185|
|AZN|AZN.O|Astrazeneca|2023 Q1||1.0879E10|185|
|AZN|AZN.O|Astrazeneca|2023 Q2||1.1416E10|185|
|AZN|AZN.O|Astrazeneca|2023 Q3|-1.68E8|1.1492E10|185|

2. **Cost Management**: The company's ability to manage costs effectively is another key factor contributing to the rise in operating profit. AstraZeneca's net margin for Q3 2023 was 10.73%, which suggests that the company is efficient in managing its expenses relative to its revenue. This, combined with the revenue growth, leads to a higher operating profit.

|code|Ticker|Name|Date|Operating Income|Net Income|market_code|
|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2022 Q4|7.79E8|9.02E8|185|
|AZN|AZN.O|Astrazeneca|2023 Q1|2.262E9|1.804E9|185|
|AZN|AZN.O|Astrazeneca|2023 Q2|2.089E9|1.82E9|185|
|AZN|AZN.O|Astrazeneca|2023 Q3|1.663E9|1.378E9|185|

In conclusion, the sharp rise in operating profit for AstraZeneca in Q3 2023 is primarily driven by revenue growth and effective cost management.